Showing 176–200 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Mburu JW, Kingwara L, Ester M, Andrew N
Background The double burden of diabetes mellitus (DM) and pulmonary tuberculosis (TB) is one of the global health challenges. Studies done in different parts of the world indicate that 12%-44% of TB disease is associated with DM. In Kenya TB-DM co-morbidity data is scarce and is…
Mohzari YA, Musawa MA, Alrashed A, Zaeri B, Damfu N, et al.
Background People living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV) prodrug and rifampicin is a key component of TB therapy, thus complicating HIV and TB coinfection management. However, there is…
Dou Y, Lu R, Su L, Lan K, Meng Z, et al.
….) dosing DTG + 3TC and rifampicin (RIF)-containing anti-TB regimens between 2020 and 2022. HIV-RNA, CD4 cell counts were collected and analysed. Results In all, 21 people with HIV (PWH) were included in this study. All the PWH were treatment-naïve and told to take DTG + 3TC q.d.…
Sani Kadri
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent Tuberculosis (TB). Stage 1: This is a pragmatic open-label m…
National Center for Research Resources (NCRR)
The primary objective of this multi-center sub-study of USPHS Study 23: "Intensive Pharmacokinetic Study of Intermittent Rifabutin and Isoniazid with Daily Efavirenz in Combination with Two Nucleoside Analogs for Treatment of HIV and Tuberculosis Co-infections," is to compare the…
Michael A. Lyons, Andrés Obregón‐Henao, Michelle E. Ramey, Allison Bauman, Stephan Pauly, et al.
…TB) drug development is to prioritize promising combination regimens from a large and growing number of possibilities. This includes demonstrating individual drug contributions to the activity of higher-order combinations. A BALB/c mouse TB infection model was used to evaluate th…
Ya Meng
Objective To explore the value of 2HRZSL/6HRL in the treatment of patients with recurrent smear positive pulmonary tuberculosis. Methods 120 patients with smear positive pulmonary tuberculosis treated at our hospital from April, 2017 to December, 2018 were selected, and divided i…
Aurélie Chauffour, J. Robert, Nicolas Véziris, Alexandra Aubry, Kévin Pethe, et al.
…ricidal and sterilizing activities in combined intermittent regimens. Q203 given twice a week in combination with one of the other long half-life compounds, rifapentine or bedaquiline, sterilized the mice footpads in 8 weeks, i.e. after a total of only 16 doses, and prevented rel…
Elizabeth A. Wynn, Christian Dide-Agossou, Reem Al Mubarak, Karen Rossmassler, Jo Hendrix, et al.
Identification of optimal antibiotic combination treatments for tuberculosis (TB) in preclinical studies is impeded by the limited information conventional pharmacodynamic (PD) markers provide about drug interactions. Measurement of individual drug activity based on colony formin…
Thammasorn Jeeraaumponwat
<b>Background:</b> Statin is found to be associated with reduced risk of tuberculosis (TB) infection, however, no study has shown the association between statin use and mortality in pulmonary TB with standard anti-TB treatment. <b>Methods:</b> We performed a retrospective cohort …
Bahareh Hajikhani, Mohammad Javad Nasiri, Brian Cody Adkinson, Taher Azimi, Farima Khalili, et al.
…ion criteria. Among these studies, 8 had rifabutin in their regimens (rifabutin group) and 16 had rifampin in their regimens (rifampin group). The estimated pooled treatment success rate was found to be 54.7% (95% CI 41.0-67.0%) in rifabutin groups and 67.5% (95% CI 55.7-77.4%) i…
Kelly E. Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, et al.
…id-resistant TB.Studies should compare high-dose first-line regimens with normal-dose regimens in terms of safety, treatment success, and acquired rifampicin resistance in patients with rifampicin-susceptible/isoniazid-resistant TB.If it is shown to be safe and efficacious, high-…
Aurélie Chauffour, J. Robert, Nicolas Véziris, Alexandra Aubry, Kévin Pethe, et al.
…ricidal and sterilizing activities in combined intermittent regimens. Telacebec given twice a week in combination with a long-half-life compound, either rifapentine or bedaquiline, sterilized mouse footpads in 8 weeks, i.e. after a total of only 16 doses, and prevented relapse du…
N.А. Lytvynenko, Olga Valentinovna Siomak, Vitaly Stephanovich Didyk, A. Kim, Marve Duka, et al.
…9 patients who died or early completed treatment with short regimens under study. Neither severe adverse event is linked to direct effect of new drugs.Conclusions. The threshold for continuation of the operational research study has been met; 100 % (> 60 %) of patients with a …
Onorikpori O Timothy, Ehiemere O Ijeoma, Maduakolam Ijeoma O, Ilo J Ijeoma
… factors affecting non-compliance to anti-tuberculosis drug regimens among pulmonary tuberculosis patients in referral hospitals, Delta state, Nigeria. Method: A quasi-experimental design involving intervention and control groups was employed, and a sample of 198 was drawn from t…
Isadora Costa Celestino, Douglas Eulálio Antunes, Diogo Fernandes dos Santos, Victor Lemos Gimenes, Fabiane Mian de Souza, et al.
…This study seeks to evaluate ADRs comparing two therapeutic regimens, MDT and ROM, used in treatment of patients with leprosy, analyzing prognostic factors regarding risk and safety. Methods: A retrospective cohort study was performed by assessing medical records of 433 patients …
Evgenia Papathanassiou
Managing non-tuberculous mycobacterial (NTM) lung disease poses challenges due to the extended treatment duration and frequent occurrence of adverse effects. Amikacin Liposome Inhalation Suspension (ALIS) is a liposomal form of amikacin, delivered through inhalation directly to t…
Soham Samajpaty, Gulnaz Minegalievna Ibragimova
The research gives new therapeutic regimen to Tuberculosis. Despite of the fact being that the current regimen is a burden on liver functioning; most of these are highly hepatotoxic and increases serum alanine aminotransferase (ALT) manifolds. In the backdrop of such a condition …
Elisa H. Ignatius, Binayak Rimal, Chandra M. Panthi, Daniel C. Belz, Christopher K. Lippincott, et al.
ABSTRACT Treatment outcomes for Mycobacteroides abscessus ( Mab , also known as Mycobacterium abscessus ) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy. Treating Mab disease is challenging due to its high baseline antibiotic…
Takanori Asakura, Shoji Suzuki, Hanako Fukano, Satoshi Okamori, Tatsuya Kusumoto, et al.
BACKGROUND: complex (MAC) in both in vitro and in vivo experiments. However, limited data are available for the clinical efficacy and adverse effects of STFX and the susceptibility of refractory MAC lung disease (MAC-LD) to the drug. Therefore, this study was aimed at evaluating …
Fabiane SM, Chiang CY, Meredith SK, Gurumurthy M, Bayissa A, et al.
…andomised comparison. The difference in proportions between regimens was estimated for favourable outcome, any grade 3/4 adverse event, QTcF increase to ≥500 ms, QTcF increase from baseline by at least 60 ms, and any grade 3/4 adverse event excluding QT events, using weighted ana…
Aristine Cheng, Hsin‐Yun Sun, Un‐In Wu, Wang‐Huei Sheng, Yee‐Chun Chen, et al.
…hods Patients failing at least two standard macrolide-based regimens were recruited from hospitals across Taiwan since August 2017. They received rifabutin (RFB > 300 mg/day) initially with azithromycin (AZR 500 mg/day) and at least one parenteral agent and were monitored ther…
Wei Zhao, Ph.D
…n the rifapentine- and moxifloxacin-containing short-course regimens (with rifampicin replaced by rifapentine and ethambutol replaced by moxifloxacin, while isoniazid and pyrazinamide remaining the same as the empirical regimen) and the empirical long-course regimen, so as to det…
Singh G, Patrikar S, Basannar DR, Bhatti VK
…es in outcomes with the use of fixed-dose combination (FDC) regimens. The aim of this study was to assess clinical effectiveness of FDC regimen as compared to the use of separate drugs in anti-TB treatment. Methods Systematic literature search was carried out. RCTs with newly dia…
Perumal R, Arodola-Oladoyinbo O, Naidoo A, Kawuma AN, Naidoo K, et al.
…armacogenetics may influence the effectiveness of treatment regimens for TB. The Improving Treatment Success Trial compared the WHO-recommended standard treatment in TB patients with an experimental regimen substituting ethambutol with moxifloxacin (MFX) in Durban, South Africa. …